Your browser doesn't support javascript.
loading
Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.
Perdrizet, Johnna; Santana, Carlos Felipe S; Senna, Thais; Alexandre, Rodrigo Fernandes; Sini de Almeida, Rodrigo; Spinardi, Julia; Wasserman, Matt.
Affiliation
  • Perdrizet J; Health Economics and Outcomes Research, Pfizer Inc, New York, NY, USA.
  • Santana CFS; Health Economics and Outcomes Research, Pfizer Inc, Sao Paulo, Brazil.
  • Senna T; Health Economics and Outcomes Research, Pfizer Inc, Sao Paulo, Brazil.
  • Alexandre RF; Health Economics and Outcomes Research, Pfizer Inc, Sao Paulo, Brazil.
  • Sini de Almeida R; Medical and Scientific Affairs, Pfizer Inc, Sao Paulo, Brazil.
  • Spinardi J; Medical and Scientific Affairs, Pfizer Inc, Sao Paulo, Brazil.
  • Wasserman M; Health Economics and Outcomes Research, Pfizer Inc, New York, NY, USA.
Hum Vaccin Immunother ; 17(4): 1162-1172, 2021 04 03.
Article in En | MEDLINE | ID: mdl-32966176

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pneumococcal Infections / Pneumococcal Vaccines Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Child / Humans / Infant Country/Region as subject: America do sul / Brasil Language: En Journal: Hum Vaccin Immunother Year: 2021 Document type: Article Affiliation country: United States Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pneumococcal Infections / Pneumococcal Vaccines Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Child / Humans / Infant Country/Region as subject: America do sul / Brasil Language: En Journal: Hum Vaccin Immunother Year: 2021 Document type: Article Affiliation country: United States Country of publication: United States